A related editorial highlights that it is important to place these findings within the context of results of other studies. The different results found in these studies are likely due to patient characteristics and trial design. The onus is on physicians to effectively translate the adverse event findings in this new study. The findings can critically inform clinical practice, guideline development, and the design of future clinical trials in IgA nephropathy. For example an elderly patient with diabetes, osteoporosis, recurrent infections, and only mild glomerulonephritis, adverse events are likely to be of far greater concern to patient and physician than the remote possibility of end stage renal disease. Conversely, for a young and otherwise healthy patient with multiple risk factors for rapid progression to end stage renal disease, an increased short-term risk for (typically reversible) adverse events might be an acceptable trade-off for the potential to delay or prevent the need for dialysis or kidney transplantation.